Recro Pharma Inc. (NASDAQ:REPH) traded up 27.6% on Wednesday . The company traded as high as $12.50 and last traded at $9.80, with a volume of 378,170 shares changing hands. The stock had previously closed at $7.68.

A number of equities research analysts have recently weighed in on the stock. Brean Capital restated a “buy” rating on shares of Recro Pharma in a report on Sunday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Recro Pharma in a research note on Saturday, May 14th. Finally, Zacks Investment Research lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, March 31st.

The company’s market cap is $91.46 million. The company has a 50 day moving average of $8.09 and a 200 day moving average of $7.24.

Recro Pharma (NASDAQ:REPH) last released its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by $0.05. The company had revenue of $17.70 million for the quarter, compared to analysts’ expectations of $13 million. Equities research analysts predict that Recro Pharma Inc. will post ($3.41) earnings per share for the current fiscal year.

In other Recro Pharma news, Director Winston J. Churchill sold 58,331 shares of the business’s stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $7.91, for a total transaction of $461,398.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Scp Vitalife Partners (Israel) sold 6,260 shares of the business’s stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $6.46, for a total transaction of $40,439.60. Following the sale, the insider now owns 783,642 shares of the company’s stock, valued at $5,062,327.32. The disclosure for this sale can be found here.

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.